Expression of Sex Hormones in Oral Squamous Cell Carcinoma: A Systematic Review on Immunohistochemical Studies.
alcohol
areca nut
breast cancer
estrogen receptors
hpv
immunohistochemistry
oral squamous cell carcinoma
sex hormones
smoking
tobacco
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
27
05
2022
entrez:
29
6
2022
pubmed:
30
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) is the most widespread oral malignancy. In the western world, smoking and alcohol remain the most common risk factors, whereas smokeless tobacco and areca nut consumption are the prevalent etiological factors in South Asia. Numerous markers were studied till date to identify the disease. However, the role of sex hormones in OSCC is poorly defined. Hormonal receptors play a role in breast cancer, prostate cancer, and human papillomavirus (HPV) driven oropharyngeal cancers. It is proven that the expression of estrogen receptor-α improved the overall survival of the patient with HPV-positive oropharyngeal cancer. Thus, this review article aims to determine the expression of sex hormones by immunohistochemistry in OSCC. This systematic review was performed with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement Criteria 2020. Relevant articles were collected from the electronic database in PubMed and Cochrane till 2021. Immunohistochemical studies on sex hormones and their role in OSCC published in English literature were included. We excluded case reports, case series, and abstract-only articles. The sample size of the selected studies varied, and these studies measured the parameters such as sex hormones and OSCC. Furthermore, all the studies used different sex hormones and their association with oral cancer through the immunohistochemical process. Thus, this review summarizes that sex hormones influence the biopathology of oral cancer and have a prognostic significance in the tumor subgroups.
Identifiants
pubmed: 35765387
doi: 10.7759/cureus.25384
pmc: PMC9233754
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e25384Informations de copyright
Copyright © 2022, R et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2 Suppl):129-32
pubmed: 21781458
Acta Odontol Scand. 2013 Nov;71(6):1513-9
pubmed: 24066884
Br J Cancer. 2011 May 10;104(10):1641-8
pubmed: 21505459
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Int J Cancer. 2019 Sep 15;145(6):1547-1557
pubmed: 31228270
J Clin Invest. 2015 May;125(5):2123-35
pubmed: 25893606
J Oncol. 2020 Jun 27;2020:9587971
pubmed: 32684934
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):89-96
pubmed: 17113977
J Steroid Biochem Mol Biol. 2003 Oct;87(1):1-25
pubmed: 14630087
Lancet. 2005 Jan 1-7;365(9453):60-2
pubmed: 15639680
World J Methodol. 2016 Mar 26;6(1):77-86
pubmed: 27018324
J Exp Clin Cancer Res. 2017 Feb 6;36(1):25
pubmed: 28166815
Int J Oncol. 2007 Jan;30(1):155-60
pubmed: 17143524
Oral Dis. 1998 Jun;4(2):120-9
pubmed: 9680901
Cancers (Basel). 2021 Nov 17;13(22):
pubmed: 34830915
Endocr Relat Cancer. 2014 Aug;21(4):555-65
pubmed: 24825747
Endocr Rev. 2018 Oct 1;39(5):664-675
pubmed: 29901737
Endocr Relat Cancer. 2004 Jun;11(2):281-93
pubmed: 15163303
Oral Oncol. 2020 Aug;107:104799
pubmed: 32446214
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Eur Arch Otorhinolaryngol. 2018 May;275(5):1289-1300
pubmed: 29582173
J Natl Cancer Inst. 2019 Sep 1;111(9):933-942
pubmed: 30715409
Clin Cancer Res. 2009 Nov 1;15(21):6529-40
pubmed: 19825947
Oncotarget. 2017 Jul 13;8(33):55511-55524
pubmed: 28903437
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pathol Oncol Res. 2007;13(3):195-202
pubmed: 17922048
Science. 2005 Mar 11;307(5715):1625-30
pubmed: 15705806